Relief Therapeutics Holding SA
SIX:RLF
Intrinsic Value
The intrinsic value of one
RLF
stock under the Base Case scenario is
73.416
CHF.
Compared to the current market price of 3.135 CHF,
Relief Therapeutics Holding SA
is
Undervalued by 96%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Fundamental Analysis
Revenue & Expenses Breakdown
Relief Therapeutics Holding SA
Balance Sheet Decomposition
Relief Therapeutics Holding SA
| Current Assets | 15.2m |
| Cash & Short-Term Investments | 12.5m |
| Receivables | 1.5m |
| Other Current Assets | 1.2m |
| Non-Current Assets | 32.8m |
| PP&E | 2.1m |
| Intangibles | 30.6m |
| Other Non-Current Assets | 113k |
Free Cash Flow Analysis
Relief Therapeutics Holding SA
| CHF | |
| Free Cash Flow | CHF |
Earnings Waterfall
Relief Therapeutics Holding SA
|
Revenue
|
4.1m
CHF
|
|
Cost of Revenue
|
-1.6m
CHF
|
|
Gross Profit
|
2.4m
CHF
|
|
Operating Expenses
|
-22.1m
CHF
|
|
Operating Income
|
-19.6m
CHF
|
|
Other Expenses
|
2.6m
CHF
|
|
Net Income
|
-17m
CHF
|
RLF Profitability Score
Profitability Due Diligence
Relief Therapeutics Holding SA's profitability score is 20/100. The higher the profitability score, the more profitable the company is.
Score
Relief Therapeutics Holding SA's profitability score is 20/100. The higher the profitability score, the more profitable the company is.
RLF Solvency Score
Solvency Due Diligence
Relief Therapeutics Holding SA's solvency score is 68/100. The higher the solvency score, the more solvent the company is.
Score
Relief Therapeutics Holding SA's solvency score is 68/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
RLF Price Targets Summary
Relief Therapeutics Holding SA
Dividends
Current shareholder yield for
RLF is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?